

# Press release

NeuroVive Pharmaceutical AB (publ)  
556595-6538



THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE SUBJECT TO LEGAL RESTRICTIONS.

## NeuroVive publishes prospectus in connection with preferential rights issue

**Lund, Sweden, 9 April 2018 – NeuroVive Pharmaceutical AB** (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the prospectus in connection with NeuroVive Pharmaceutical AB's (publ) ("NeuroVive" or the "Company") previously announced preferential rights issue ("Rights Issue") and the admission to trading of the Company's shares on Nasdaq Stockholm has been approved and registered by the Swedish Financial Supervisory Authority as of 9 April 2018. The prospectus, application forms and other relevant information are available at the Company's office and can be downloaded from the Company's website, [www.neurovive.com](http://www.neurovive.com). The prospectus will also be available from the Swedish Financial Supervisory Authority's website, [www.fi.se](http://www.fi.se), Stockholm Corporate Finance AB's website, [www.stockholmcorp.se](http://www.stockholmcorp.se), and from Hagberg & Aneborn Fondkommission AB's website, [www.hagberganeborn.se](http://www.hagberganeborn.se).

### Summary of the Rights Issue

At an extraordinary general meeting on 22 March 2018, the Company resolved in accordance with the Board proposal on a Right Issue, whereby the Company's shareholders have preferential rights to subscribe for new shares and warrants (units) in relation to the number of shares they owned on the record date of 5 April 2018 at a subscription price of SEK 8 per unit, corresponding to a subscription price of SEK 2 per share. The warrants are issued free of charge. The Rights Issue entitles the holder of one (1) existing share in Company to three (3) unit rights. Sixteen (16) unit rights entitle the holder to one (1) unit, comprising four (4) new shares and one (1) warrant of the 2018:1 series. On full subscription of the Rights Issue, the Company will raise approximately SEK 78.5 million before issue costs. If the warrants issued in the Rights Issue are exercised in full, the Company will raise approximately an additional SEK 37.3 million before issue costs.

### Schedule for the Rights Issue in brief (all dates refer to 2018)

Tuesday, 10 April	Subscription period starts
Tuesday, 10 April	Trading in unit rights starts
Friday, 20 April	Trading in unit rights ends
Tuesday, 24 April	Subscription period ends
Approx. Friday, 27 April	Announcement of outcome of Rights Issue

### Advisers

NeuroVive has appointed Stockholm Corporate Finance AB as financial advisor, Advokatfirman Lindahl KB as legal advisor and Hagberg & Aneborn Fondkommission AB is the issuing institution in connection with the Rights Issue.

*This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on 9 April 2018.*

**NeuroVive Pharmaceutical AB (publ)** - the mitochondrial medicine company. The company is listed on Nasdaq Stockholm, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC Markets Group Inc market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTCQX Best Market. Investors can find Real-Time quotes and market information for the company at [www.otcmarkets.com/stock/NEVPF/quote](http://www.otcmarkets.com/stock/NEVPF/quote)

# Press release

NeuroVive Pharmaceutical AB (publ)  
556595-6538



## For more information please contact:

Daniel Schale, Director of Communications  
+46 (0)46-275 62 21, [ir@neurovive.com](mailto:ir@neurovive.com)

## NeuroVive Pharmaceutical AB (publ)

Medicon Village, SE-223 81 Lund, Sweden  
Tel: +46 (0)46 275 62 20 (switchboard)  
[info@neurovive.com](mailto:info@neurovive.com), [www.neurovive.com](http://www.neurovive.com)

## About NeuroVive

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company's strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

## About Stockholm Corporate Finance

Stockholm Corporate Finance is a Swedish, independent and privately owned financial advisor offering qualified transaction based advisory services by acting in capital raisings, changes in ownership, acquisition, merger and acquisitions (M&A) in listed and privately held companies. Stockholm Corporate Finance is the exclusive Swedish partner in the global network of M&A Worldwide consisting of 43 M&A advisors and investment banks in 45 countries. Stockholm Corporate Finance is an investment firm which is supervised by the FSA and is a member of the trade organization SwedSec Licensing AB. [www.stockholmcorp.se](http://www.stockholmcorp.se)

## IMPORTANT INFORMATION

In certain jurisdictions, the publication or distribution of this press release may be subject to restrictions according to law and persons in those jurisdictions where this press release has been published or distributed should inform themselves about and abide by such restrictions. This press release does not contain or constitute an invitation or an offer to acquire, subscribe for or otherwise trade in shares or other securities in NeuroVive.

This press release may not be announced, published or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or any other country where such action is wholly or partially subject to legal restrictions. Nor may the information in this press release be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions. Failure to comply with this instruction may result in a violation of the United States Securities Act of 1933 (the "Securities Act") or laws applicable in other jurisdictions.